Albendazole nanocrystal with high bioavailability and preparation method thereof

Through the combination with natural glycoside stabilizers and wet medium grinding, high bioavailability albendazole nanocrystals were prepared, which solved the problem of low solubility and bioavailability of albendazole and realized the drug Efficient absorption and safe production.

CN118948779AActive Publication Date: 2024-11-15CHINA PHARM UNIV

Patent Information

Application Number
CN202411028690.1
Authority / Receiving Office
CN · China
Patent Type
Applications(China)
Current Assignee / Owner
Filing Date
2024-07-30
Publication Date
2024-11-15
Estimated Expiration
2044-07-30

AI Technical Summary

Technical Problem

As a first-line broad-spectrum antiperspirant, albendazole has problems such as poor water solubility, low solubility, poor intestinal absorption and low bioavailability, resulting in adverse drug reactions.

Method used

The nanocrystals are prepared by mixing natural-derived glycoside stabilizers with albendazole and wet medium grinding to improve the solubility and bioavailability of the drug, avoid the use of organic solvents, and simplify the process.

Benefits of technology

It significantly improves the solubility and bioavailability of albendazole, reduces the risk of adverse reactions, achieves simplification of the process and reduces costs, and is suitable for large-scale production.

✦ Generated by Eureka AI based on patent content.

Smart Images

  • Figure CN118948779A_ABST
    Figure CN118948779A_ABST
Patent Text Reader

Abstract

The invention discloses an albendazole nanocrystal with high bioavailability and a preparation method of the albendazole nanocrystal. The nanocrystal is prepared by mixing albendazole, a natural glycoside stabilizer and water to form a suspension and grinding the suspension by adopting a wet medium, the average particle size is 100 to 500 nm. The nanocrystal is obtained by dispersing albendazole in a natural source glycoside solution and performing nanocrystallization treatment, the drug loading capacity is high, and the solubility and dissolution rate of albendazole can be greatly improved, so that the absorption of albendazole is improved, and the bioavailability of albendazole is improved. The stabilizer adopted by the invention is rich in resource, natural and economical, the preparation process is simple, efficient and safe, and is suitable for industrial production, and an intermediate with high bioavailability is provided for an albendazole preparation.
Need to check novelty before this filing date? Find Prior Art

Description

Technical Field

[0001] The invention belongs to the technical field of medicine, and in particular relates to a high-bioavailability albendazole nanocrystal and a preparation method thereof. Background Art

[0002] Albendazole, chemical name is 5-(propylthio)-2-benzimidazolecarbamic acid methyl ester, molecular formula C 12 H 15 N 3 O 2 S, molecular weight: 265.33. Albendazole is a first-line broad-spectrum anthelmintic that can effectively treat intestinal and systemic parasitic diseases. However, this drug belongs to BCS II class drugs, has poor water solubility, low solubility, poor intestinal absorption, low distribution in plasma and liver tissue, low bioavailability, and high-dose long-term medication is prone to adverse drug reactions. Therefore, it is necessary to take appropriate methods to improve its solubility, increase its absorption in the body, and improve its bioavailability.

[0003] Nanocrystals are a submicron colloidal dispersion system composed only of drugs and a small amount of stabilizers. They have a high drug loading capacity and a simple preparation process. Through surface modification, they can achieve targeting to the lesion site and significantly improve the solubility and bioavailability of poorly soluble drugs. They are an important strategy to increase the success rate of new drug research and development, reduce adverse reactions, and improve drug efficacy.

[0004] The preparation methods of nanocrystals are divided into top-down and bottom-up methods. The top-down method is to reduce the size of solid drug particles to the nanometer range by high-pressure homogenization or nano-grinding; the bottom-up method refers to dissolving the drug in a solvent, then precipitating it by adding an anti-solvent, and finally obtaining a nanometer powder by spraying or freeze drying. The wet ball milling method has the advantages of mature technology, simple operation, wide application range, narrow particle size distribution of the prepared nano-drugs, and no organic solvent residue. It has become the most commonly used preparation method for currently marketed nano-drugs (Malamatari M, Taylor K MG, Malamataris S, et al. Pharmaceutical nanocrystals: production by wet milling and applications [J]. Drug Discov Today, 2018, 23 (3): 534-547).

[0005] In order to improve the solubility of albendazole, researchers have successively developed and studied different preparations such as solid dispersions, inclusion compounds and liposomes. However, the above preparations have problems such as limited ability to improve the bioavailability of albendazole, excessive excipient load, and difficulty in industrialization.

[0006] At present, the research on albendazole nanocrystals mostly uses synthetic polymers such as poloxamer 188, PVP K30, and Tween 80 as stabilizers, and adopts preparation methods such as high-pressure homogenization or anti-solvent precipitation. There are problems such as high process energy consumption, use of organic solvents, and large amounts of stabilizers. Summary of the invention

[0007] Purpose of the invention: The purpose of the present invention is to provide a highly bioavailable albendazole nanocrystal and a preparation method thereof in view of the deficiencies of the prior art. The present invention prepares albendazole nanocrystals by screening a natural source glycoside stabilizer and optimizing the wet media grinding process, thereby improving the bioavailability of albendazole. The preparation method is simple and easy to scale up production. The prepared albendazole nanocrystals effectively exert the antiparasitic therapeutic effect of albendazole.

[0008] Technical solution: The purpose of the present invention is achieved through the following technical solution:

[0009] The invention provides an albendazole nanocrystal with high bioavailability. The nanocrystal is prepared by mixing albendazole, a natural glycoside stabilizer and water to form a suspension, and grinding the suspension with wet media; the average particle size is 100-500nm.

[0010] The present invention uses a natural source glycoside stabilizer and albendazole to mix and prepare albendazole nanocrystals, and fully utilizes the stabilizer's characteristics: 1) the stabilizer is coated on the surface of albendazole particles by physical adsorption or hydrogen bonding to increase steric hindrance to prevent drug particles from aggregating; 2) the drug molecules can be maintained in a supersaturated state for a certain period of time; 3) the solubility of the drug is increased. The present invention's experiments show that the saturated solubility of albendazole nanocrystals in water, pH 1.0 hydrochloric acid solution, pH 4.5 acetate buffer, and pH 6.8 phosphate buffer is about 3 to 2500 times higher than that of albendazole.

[0011] A preferred embodiment of the present invention is that the average particle size of the albendazole nanocrystals is 100 to 300 nm, and the zeta potential ranges from -30 to -20 mV.

[0012] Preferably, the natural source stabilizer is selected from one of tea saponin or rubusoside.

[0013] More preferably, the natural glycoside stabilizer is selected from tea saponin. Tea saponin is used as a stabilizer because it is widely available, cheap, easy to obtain, and green and safe.

[0014] Preferably, the mass ratio of the albendazole to the natural glycoside stabilizer is 10:1 to 10:12; and the concentration of the albendazole in the suspension is 0.2 to 3.0%.

[0015] Further preferably, the mass ratio of the albendazole to the natural glycoside stabilizer is 5:1 to 5:4; and the concentration of the albendazole in the suspension is 0.5 to 2.5%.

[0016] The invention optimizes the type and dosage of the stabilizer and the wet medium grinding process parameters, thereby improving the solubility and in vivo bioavailability of the poorly soluble drug albendazole.

[0017] The present invention also provides a method for preparing the albendazole nanocrystals with high bioavailability, comprising the following steps:

[0018] (1) fully mixing a natural glycoside stabilizer and water to form a stabilizer solution A;

[0019] (2) adding albendazole to the stabilizer solution A obtained in step (1), stirring to suspend the drug therein, to obtain albendazole crude suspension B;

[0020] (3) subjecting the albendazole coarse suspension B obtained in step (2) to wet medium grinding to obtain an albendazole nanosuspension, i.e., the albendazole nanocrystals.

[0021] The present invention uses nano-grinding technology to process albendazole. During the grinding process, the drug and the stabilizer are co-grinded to fully prevent the aggregation of drug particles and ensure the stability of the suspension. The stability for 28 days is investigated under room temperature and low temperature conditions, and the nano-crystal particle size and PDI do not change significantly.

[0022] Preferably, in step (3), the process parameters of the wet medium grinding are: grinding time 2 to 8 hours, grinding speed controlled at 300 to 700 rpm, liquid-to-bead ratio 1:(2-8).

[0023] Further preferably, the process parameters of the wet medium grinding are: grinding time 3 to 7 hours, grinding speed controlled at 400 to 700 rpm, liquid-to-bead ratio 1:(4-8).

[0024] Preferably, in step (3), the particle size of the grinding beads used in the wet medium grinding is 0.2-0.5 mm, and the material is zirconia, yttrium-stabilized zirconia or stainless steel.

[0025] The invention also provides a freeze-dried solid powder of albendazole nanocrystals, which is prepared by freeze-drying the albendazole nanocrystals.

[0026] Preferably, the lyoprotectant used in the freeze drying is selected from any one of sucrose, lactose, fructose, mannitol, sorbitol, xylitol, polyethylene glycol 4000 or a combination thereof.

[0027] The present invention also provides a pharmaceutical preparation, which is prepared by mixing the albendazole nanocrystal freeze-dried solid powder with pharmaceutically acceptable excipients.

[0028] The dosage form is tablet, capsule, pellet or suspension.

[0029] In the present invention, the "liquid-to-bead ratio" is the ratio of the suspension to the grinding beads used in the wet media grinding process, and the unit is "v:w".

[0030] Beneficial effects:

[0031] 1. The albendazole nanocrystals prepared by the present invention improve the solubility of albendazole, have good stability, can be mass-produced, and provide a good intermediate for preparing other albendazole preparations.

[0032] 2. The present invention realizes a process for preparing albendazole nanosuspension by wet medium grinding. The preparation process is simple and feasible, does not use organic solvents, has low production cost, is controllable, is convenient for large-scale industrial production, and is conducive to market promotion.

[0033] 3. The albendazole nanocrystals prepared by the present invention have small particle size, small amount of stabilizer used, and high drug loading capacity.

[0034] 4. The albendazole nanocrystals prepared by the present invention greatly improve the solubility and bioavailability of albendazole; they can be used to prepare various albendazole preparations and have good application prospects. BRIEF DESCRIPTION OF THE DRAWINGS

[0035] Figure 1 The results of the study on the effect of stabilizer types on the particle size of albendazole nanocrystals are shown in Figure 2.

[0036] Figure 2 The results of the investigation on the effect of grinding speed on the particle size of nanocrystals;

[0037] Figure 3 The results of the investigation on the effect of grinding time on the particle size of nanocrystals;

[0038] Figure 4 The results of the investigation on the effect of liquid-to-drop ratio on the particle size of nanocrystals;

[0039] Figure 5 The short-term stability results of albendazole nanocrystals at 4°C and room temperature;

[0040] Figure 6 The scanning electron micrographs of albendazole API (A) and nanocrystals (B);

[0041] Figure 7 X-ray diffraction analysis (XRPD) curves of albendazole, a physical mixture of albendazole and a stabilizer, and albendazole nanocrystalline powder;

[0042] Figure 8 The blood concentration-time curves of the albendazole bulk drug and nanocrystals in Example 1. DETAILED DESCRIPTION

[0043] The technical solution of the present invention is described in detail below through specific embodiments, but the protection scope of the present invention is not limited to the embodiments.

[0044] If no specific techniques or conditions are specified in the examples, the techniques or conditions described in the literature in the field or the product instructions are used. If no manufacturer is specified for the reagents or instruments used, they are all conventional products that can be purchased through regular channels.

[0045] The experimental methods in the following examples are conventional methods unless otherwise specified. The experimental materials used in the following examples are commercially available products unless otherwise specified.

[0046] Albendazole raw material was purchased from Guangxi Yiyuan Biotechnology Co., Ltd. (purity>98%).

[0047] Tea saponin was purchased from Hunan Hanqing Biotechnology Co., Ltd. (purity ≥ 90%).

[0048] Rubusoside was purchased from Xi'an Jushengyuan Biotechnology Co., Ltd. (purity ≥ 90%).

[0049] Example 1 Preparation of Albendazole Nanocrystals

[0050] (1) Thoroughly mix tea saponin and water and stir with a magnetic stirrer to form a stabilizer solution A;

[0051] (2) adding albendazole to the stabilizer solution A obtained in step (1) at a mass ratio of albendazole raw material to tea saponin of 5:3, stirring to suspend the drug therein, and obtaining albendazole crude suspension B;

[0052] (3) The coarse albendazole suspension B obtained in step (2) is transferred to a grinding jar of a planetary ball mill, and wet-milled with zirconium oxide grinding beads having a diameter of 0.25-0.3 mm, and shaken evenly, and the coarse suspension B and zirconium oxide grinding beads are added to the grinding jar in a ratio of 1:4 (v / w), and milled at 500 rpm for 6 h. After milling, the grinding beads are separated to obtain an albendazole nanosuspension, i.e., albendazole nanocrystals. The concentration of albendazole in the albendazole nanosuspension is 1.0%.

[0053] The average particle size of albendazole nanocrystals was 186.9±1.3 nm, the PDI was 0.187±0.006, and the zeta potential was -25.3±0.5 mV.

[0054] Example 2 Preparation of Albendazole Nanocrystals

[0055] (1) Thoroughly mix tea saponin and water and stir with a magnetic stirrer to form a stabilizer solution A;

[0056] (2) adding albendazole to the stabilizer solution A obtained in step (1) at a mass ratio of albendazole raw material to tea saponin stabilizer of 10:1, stirring to suspend the drug therein, and obtaining albendazole crude suspension B;

[0057] (3) The coarse albendazole suspension B obtained in step (2) is transferred to a grinding jar of a planetary ball mill, and wet-milled with zirconium oxide grinding beads having a diameter of 0.25-0.3 mm, and shaken evenly, and the coarse suspension B and zirconium oxide grinding beads are added to the grinding jar in a ratio of 1:4 (v / w), and milled at 500 rpm for 6 h. After milling, the grinding beads are separated to obtain an albendazole nanosuspension, i.e., albendazole nanocrystals. The concentration of albendazole in the albendazole nanosuspension is 1.0%.

[0058] The average particle size of albendazole nanocrystals was 330.9±6.7 nm, the PDI was 0.236±0.010, and the zeta potential was -25.1±1.2 mV.

[0059] Example 3 Preparation of Albendazole Nanocrystals

[0060] (1) Thoroughly mix tea saponin and water and stir with a magnetic stirrer to form a stabilizer solution A;

[0061] (2) adding albendazole to the stabilizer solution A obtained in step (1) at a mass ratio of albendazole raw material to tea saponin stabilizer of 1:1, stirring to suspend the drug therein, and obtaining albendazole crude suspension B;

[0062] (3) The coarse albendazole suspension B obtained in step (2) is transferred to a grinding jar of a planetary ball mill, and wet-milled with zirconium oxide grinding beads having a diameter of 0.25-0.3 mm, and shaken evenly, and the coarse suspension B and zirconium oxide grinding beads are added to the grinding jar in a ratio of 1:4 (v / w), and milled at 500 rpm for 6 h. After milling, the grinding beads are separated to obtain an albendazole nanosuspension, i.e., albendazole nanocrystals. The concentration of albendazole in the albendazole nanosuspension is 1.0%.

[0063] The average particle size of albendazole nanocrystals was 216.0±7.5 nm, the PDI was 0.205±0.009, and the zeta potential was -22.2±0.4 mV.

[0064] Example 4 Preparation of Albendazole Nanocrystals

[0065] (1) Thoroughly mix tea saponin and water and stir with a magnetic stirrer to form a stabilizer solution A;

[0066] (2) adding albendazole to the stabilizer solution A obtained in step (1) at a mass ratio of albendazole raw material to tea saponin stabilizer of 5:6, stirring to suspend the drug therein, to obtain albendazole crude suspension B;

[0067] (3) The coarse albendazole suspension B obtained in step (2) is transferred to a grinding jar of a planetary ball mill, and wet-milled with zirconium oxide grinding beads having a diameter of 0.25-0.3 mm, and shaken evenly, and the coarse suspension B and zirconium oxide grinding beads are added to the grinding jar in a ratio of 1:4 (v / w), and milled at 500 rpm for 6 h. After milling, the grinding beads are separated to obtain an albendazole nanosuspension, i.e., albendazole nanocrystals. The concentration of albendazole in the albendazole nanosuspension is 0.5%.

[0068] The average particle size of albendazole nanocrystals was 215.2±1.2 nm, the PDI was 0.277±0.012, and the zeta potential was -21.3±3.0 mV.

[0069] Example 5 Preparation of Albendazole Nanocrystals

[0070] (1) Thoroughly mix tea saponin and water and stir with a magnetic stirrer to form a stabilizer solution A;

[0071] (2) adding albendazole to the stabilizer solution A obtained in step (1) at a mass ratio of albendazole raw material to tea saponin stabilizer of 25:6, stirring to suspend the drug therein, and obtaining albendazole crude suspension B;

[0072] (3) The coarse albendazole suspension B obtained in step (2) is transferred to a grinding jar of a planetary ball mill, and wet-milled with zirconium oxide grinding beads having a diameter of 0.25-0.3 mm, and shaken evenly, and the coarse suspension B and zirconium oxide grinding beads are added to the grinding jar in a ratio of 1:4 (v / w), and milled at 500 rpm for 6 h. After milling, the grinding beads are separated to obtain an albendazole nanosuspension, i.e., albendazole nanocrystals. The concentration of albendazole in the albendazole nanosuspension is 2.5%.

[0073] The average particle size of albendazole nanocrystals was 246.2±26.4 nm, the PDI was 0.138±0.018, and the zeta potential was -24.3±0.8 mV.

[0074] Comparative Example 1

[0075] Poloxamer 407 was used as a stabilizer, the mass ratio of albendazole raw material to stabilizer was 5:3, and nanocrystals were prepared according to the parameters of Example 1. The average particle size of albendazole nanocrystals was 377.9±4.8nm, the PDI was 0.236±0.031, and the zeta potential was -13.3±0.4mV. This shows that the average particle size and PDI of the nanocrystals prepared with poloxamer 407 as a stabilizer were higher than those of the nanocrystals prepared with tea saponin as a stabilizer, and the absolute value of the potential of the nanocrystals prepared with poloxamer 407 as a stabilizer was lower than that of the nanocrystals prepared with tea saponin as a stabilizer.

[0076] Example 6 Screening of stabilizer types

[0077] The albendazole raw material and different stabilizers were weighed at a mass ratio of 5:3, distilled water was added to make the concentration of albendazole in the suspension 1.0%, and a magnetic stirrer was used to stir to obtain a coarse suspension. The coarse suspension and zirconium oxide grinding beads with a diameter of 0.25-0.3 mm were transferred to a grinding jar of a planetary ball mill at a ratio of 1:4 (v / w), and ground at a rotation speed of 500 rpm for 6 hours. After grinding, the grinding beads were separated to obtain an albendazole nanosuspension.

[0078] The stabilizers selected were glycyrrhizic acid (GA), tea saponin (TS) and rubusoside (RUB), and the particle size and polydispersity index (PDI) of each nanosuspension were measured using a particle size potentiometer.

[0079] The results are as follows Figure 1 As shown in the figure, among the three stabilizers, the particle size and PDI of albendazole nanosuspension stabilized by tea saponin were better, and the order of particle size was tea saponin (TS) < glycyrrhizic acid (GA) < rubusoside (RUB).

[0080] Example 7 Grinding Speed ​​Investigation

[0081] Zirconia beads with a diameter of 0.25-0.3 mm were used for wet grinding. The mass ratio of albendazole API to stabilizer was 10:3. The concentration of albendazole in the albendazole nanosuspension was 1.0%. The suspension and zirconium oxide grinding beads were added to a grinding jar in a ratio of 1:4 (v / w) and ground at 300-600 rpm for 6 h. Different grinding speeds were investigated with average particle size and PDI as evaluation indicators.

[0082] like Figure 2 As shown, it was found that 500 rpm grinding effect was better.

[0083] Example 8 Grinding time investigation

[0084] Zirconia beads with a diameter of 0.25-0.3 mm were used for wet grinding. The mass ratio of albendazole API to stabilizer was 10:3. The concentration of albendazole in the albendazole nanosuspension was 1.0%. The suspension and zirconium oxide grinding beads were added to a grinding jar in a ratio of 1:4 (v / w) and ground at 500 rpm for 3 to 7 h. Different grinding times were investigated with average particle size and PDI as evaluation indicators.

[0085] like Figure 3 As shown, it was found that grinding for 6 hours had a better effect.

[0086] Example 9 Liquid-to-bead ratio study

[0087] Zirconia beads with a diameter of 0.25-0.3 mm were used for wet grinding. The mass ratio of albendazole API to stabilizer was 10:3. The concentration of albendazole in the albendazole nanosuspension was 1.0%. The suspension and zirconium oxide grinding beads were added to the grinding jar in ratios of 1:2, 1:4, and 1:8 (v / w) and ground at 500 rpm for 6 h. The average particle size and PDI were used as evaluation indicators to investigate different liquid-to-bead ratios.

[0088] like Figure 4 As shown, it was found that the grinding effect was better when the liquid-to-bead ratio was 1:4.

[0089] Example 10 Study on the stability of albendazole nanosuspension

[0090] The albendazole nanosuspension prepared in Example 1 was placed at 4°C and room temperature for 28 days. A small amount of the nanocrystal suspension was taken at the same time period of 0, 7, 14, 21, and 28 days, and the particle size, PDI, and ζ potential were measured using a Malvern laser particle size analyzer to investigate the short-term stability within 28 days. The experimental results are shown in Figure 5 .

[0091] in, Figure 5 A is the particle size and PDI results of albendazole nanosuspension at 4°C; Figure 5 B is the zeta potential result of albendazole nanosuspension at 4°C; Figure 5 C is the particle size and PDI results of albendazole nanosuspension at room temperature; Figure 5 D is the zeta potential result of albendazole nanosuspension at room temperature.

[0092] Depend on Figure 5It can be seen that the average particle size, PDI and ζ potential of the nanosuspension at day 0 are 186.2±0.7nm, 0.202±0.011, -25.1±0.8mV, respectively. At 4℃ and room temperature, the average particle size and PDI of albendazole nanocrystals within 28 days are stable at about 186-189nm and 0.195-0.205, respectively. At 4℃, the absolute value of ζ potential is above 23mV, which can maintain good stability. At room temperature, the ζ potential decreases to a certain extent, but the absolute value is above 20mV.

[0093] Example 11 Screening of Lyoprotectants

[0094] An appropriate amount of freeze-drying protective agent was added to the albendazole nanosuspension prepared in Example 1, and the mixture was evenly mixed. The mixture was transferred to a vial, pre-frozen at -80°C for 12 h, and then placed in a freeze dryer and freeze-dried at a vacuum degree of 20 Pa and -80°C for 48 h to obtain a nanocrystalline solid powder.

[0095] After screening lactose, mannitol, PEG4000, and lactose-mannitol (1:1, 1:2), it was found that when lactose was used as a lyophilization protective agent, the appearance, redispersion speed and particle size of the nanocrystalline lyophilized powder after reconstitution were ideal, so lactose was selected as the lyophilization protective agent.

[0096] Example 12 Characterization of Albendazole Nanocrystals

[0097] (1) Scanning electron microscopy (SEM)

[0098] The morphology of the albendazole bulk drug and the nanocrystals prepared in Example 1 were analyzed using a scanning electron microscope. Figure 6 .in, Figure 6 A is the scanning electron microscope image of albendazole raw material. Figure 6 B is a scanning electron microscope image of albendazole nanocrystals. It can be observed from the image that the nanocrystals are spherical nanoparticles of uniform size, and their particle size is significantly smaller than that of the raw material drug.

[0099] (2) Powder X-ray diffraction analysis (XRPD)

[0100] Albendazole API, physical mixture (API and stabilizer) and albendazole nanocrystals prepared in Example 1 were respectively taken, and a Cu-Kα target was used, the wavelength was set to 1.540562nm, the tube high voltage was 40kV, the tube current was 40mA, the scanning range was 3-40° (2θ range), the scanning wavelength was 10° / min, and the step length was 0.02°, and the powder-X-ray diffraction pattern was measured. The XRPD curve is as follows Figure 7 shown.

[0101] It can be seen from the figure that the characteristic peaks of albendazole at 2θ of 6.8°, 11.2°, 17.9°, and 24.7° have basically not changed in the nanocrystalline powder, while the peak intensity is significantly reduced. This may be because the particle size is reduced after being prepared into nanocrystals, part of the drug maintains the original crystal form, and the crystallinity of the other part is reduced and transformed into an amorphous form, which requires less energy to overcome the lattice force.

[0102] Example 13 Study on the saturated solubility of albendazole nanocrystals

[0103] Take an excess of the raw material drug, the physical mixture (raw material drug and stabilizer) and the nanocrystal prepared in Example 1 and add them to water, pH 1.0 hydrochloric acid solution, pH 4.5 acetate buffer, and pH 6.8 phosphate buffer, respectively, place them in a 37°C constant temperature shaking shaker, shake at 150 rpm for 48 hours to obtain a supersaturated solution, centrifuge at 10000 rpm for 10 minutes, take the supernatant, filter, and measure by HPLC. As shown in Table 1, compared with the raw material drug and the physical mixture, the saturated solubility of the albendazole nanocrystal powder in water, pH 4.5 acetate buffer, and pH 6.8 phosphate buffer is 1700 to 2500 times that of the raw material drug, and in pH 1.0 hydrochloric acid solution is 3 times that of the raw material drug.

[0104] Table 1 Saturated solubility of API, physical mixture and nanocrystal (37°C) (n=3)

[0105] medium API (μg / mL) Physical mixture (μg / mL) Nanocrystals (μg / mL) water 0.62±0.07 14.56±1.31 <![CDATA[1602.67±58.05 *** ]]> pH 1.0 hydrochloric acid solution 1165.06±2.14 1216.60±7.53 <![CDATA[3410.57±27.15 *** ]]> pH 4.5 Acetate Buffer 0.88±0.02 11.60±3.18 <![CDATA[1584.68±40.63 *** ]]> pH 6.8 phosphate buffer 0.62±0.03 7.89±1.64 <![CDATA[1604.32±24.03 *** ]]>

[0106] *** p<0.001, comparison between nanocrystal group and API group

[0107] Example 14 In vitro intestinal absorption study of albendazole nanocrystals

[0108] Six healthy SD rats, male, 5 weeks old, weighing 180-200 g, were provided by Jiangsu Qinglongshan Biotechnology Co., Ltd.

[0109] Rats were fasted for 12 hours before the experiment and were free to drink water. Male SD rats were randomly divided into two groups, namely the raw material group and the nanocrystal group. After the rats were anesthetized, the abdominal cavity was opened along the midline of the abdomen, and the duodenum, jejunum, ileum, and colon segments of about 10 cm were separated. Each segment was turned over so that the mucosal layer was outside and the serosal layer was inside. One end of the intestinal segment was ligated to form a sac and placed in 37°C KR buffer for equilibration for 10 minutes. The other end was fixed to the sampling port, 1.5mL of 37°C blank KR buffer was added, and the intestinal sac was placed vertically in a test tube containing 40mL KR buffer, in which the concentration of albendazole was 0.2mg / mL, and 95% O was continuously passed into the test tube. 2 +5% CO2 Mixed gas was added to maintain the activity of the intestinal sac. 0.2 mL of samples were taken from the intestinal sac at 30, 60, 90, and 120 min, and an equal volume of blank KR buffer was added. After the experiment, the length L and inner diameter R of each intestinal segment were measured. The drug concentration of the intestinal sac sample solution at each time point was determined by HPLC, and the apparent permeability coefficient P of each intestinal segment was calculated. app The experimental results are shown in Table 2. The apparent permeability coefficient P of the nanocrystal group in each intestinal segment app It was significantly improved compared with the raw material drug group.

[0110] Table 2 Comparison of intestinal absorption results of nanocrystals and raw materials (n=3)

[0111]

[0112] ** p<0.01, comparison between nanocrystal group and API group

[0113] Example 15 Pharmacokinetic Study of Albendazole Nanosuspension

[0114] 1. Animal grouping and drug administration

[0115] One hundred healthy ICR mice, male, 5 weeks old, weighing 20-30 g, were provided by Jiangsu Qinglongshan Biotechnology Co., Ltd.

[0116] Scheme: The mice were randomly divided into two groups. The mice were fasted for 12 hours before administration and had free access to water. Albendazole and the albendazole nanosuspension prepared in Example 1 were administered by gavage at a dosage of 50 mg / kg.

[0117] 2. Sample collection:

[0118] Blood was collected from the retinal venous plexus at 0.5, 1, 2, 3, 4, 6, 8, 10, 12, and 24 hours after administration, placed in pre-heparinized EP tubes, centrifuged at 12000 rpm at 4°C for 10 min, and the plasma was separated and placed in labeled EP tubes and stored in a -80°C refrigerator.

[0119] 3. Plasma sample processing method

[0120] Take 100 μL of plasma sample, add 30 μL of 1 μg / mL tobendazole internal standard solution, vortex mix, add 600 μL of methanol, vortex thoroughly for 3 min to precipitate protein, centrifuge at 10000 r / min for 10 min, aspirate the supernatant, blow dry with nitrogen in a water bath at 45°C, redissolve the residue with 100 μL of initial mobile phase acetonitrile-0.1% acetic acid water (20:80, v / v), vortex thoroughly, centrifuge at 10000 r / min for 10 min, aspirate the supernatant, perform HPLC quantitative analysis, determine the plasma drug concentration, and draw the blood drug concentration-time curve.

[0121] 4. Data Analysis

[0122] Phoenix WinNonlin8.1.0 pharmacokinetic software was used to process the blood concentration data of albendazole metabolite albendazole sulfoxide and calculate the pharmacokinetic parameters AUC, T max , C max wait.

[0123] 5. Drug-time curve after administration

[0124] The plasma was processed and tested to obtain the drug-time curve of albendazole metabolite albendazole sulfoxide (ABZSO) at each time point (e.g. Figure 8 The peak blood concentration of ABZSO in the nanocrystal group was C max It was significantly higher than the raw material drug group, and the area under the drug-time curve (AUC) increased significantly, indicating that the oral bioavailability of the drug in the body increased significantly and the amount of drug absorbed increased.

[0125] 6. Pharmacokinetic parameters

[0126] After fitting the non-compartmental model, the main pharmacokinetic parameters are shown in Table 3. The results showed that compared with the raw material drug group, the blood drug concentration of the nanocrystal group increased significantly, and the C max 5.0 times that of the API group; AUC of ABZSO 0→t It is 4.7 times that of the raw material drug group, indicating that the nanocrystals prepared with tea saponin as a stabilizer effectively increase the oral bioavailability of the drug in the body.

[0127] Table 3 Comparison of pharmacokinetic results of nanocrystals and raw materials (n=5)

[0128] parameter unit API Nanocrystals <![CDATA[T max ]]> h 2 1 <![CDATA[C max ]]> mg / L 4.91 24.46 <![CDATA[AUC 0→t ]]> h*mg / L 34.92 162.55 <![CDATA[AUC 0→∞ ]]> h*mg / L 35.46 163.88

[0129] As described above, although the present invention has been shown and described with reference to specific preferred embodiments, it should not be construed as limiting the present invention itself. Various changes in form and details may be made without departing from the spirit and scope of the present invention as defined in the appended claims.

Claims

1. A highly bioavailable albendazole nanocrystal, It is characterized in that The nanocrystals are prepared by mixing albendazole, a natural glycoside stabilizer and water to form a suspension, and grinding the suspension with a wet medium; the average particle size is 100-500nm.

2. The highly bioavailable albendazole nanocrystals according to claim 1, It is characterized in that The average particle size of the albendazole nanocrystals is 100 to 300 nm, and the zeta potential ranges from -30 to -20 mV.

3. The highly bioavailable albendazole nanocrystals according to claim 1, It is characterized in that The natural glycoside stabilizer is selected from the group consisting of tea saponin and rubusoside.

4. The highly bioavailable albendazole nanocrystals according to claim 3, It is characterized in that The natural glycoside stabilizer is selected from tea saponin.

5. The highly bioavailable albendazole nanocrystals according to claim 1, It is characterized in that The mass ratio of the albendazole to the natural glycoside stabilizer is 10:1-10:12; the concentration of the albendazole in the suspension is 0.2-3.0%.

6. The highly bioavailable albendazole nanocrystals according to claim 5, It is characterized in that The mass ratio of the albendazole to the natural glycoside stabilizer is 5:1-5:4; and the concentration of the albendazole in the suspension is 0.5-2.5%.

7. A method for preparing the highly bioavailable albendazole nanocrystals according to any one of claims 1 to 6, It is characterized in that The following steps are involved: (1) fully mixing a natural glycoside stabilizer and water to form a stabilizer solution A; (2) adding albendazole to the stabilizer solution A obtained in step (1), stirring to suspend the drug therein, to obtain albendazole crude suspension B; (3) subjecting the albendazole coarse suspension B obtained in step (2) to wet medium grinding to obtain an albendazole nanosuspension, i.e., the albendazole nanocrystals.

8. The preparation method according to claim 7, It is characterized in that In step (3), the process parameters of the wet medium grinding are: grinding time 2 to 8 hours, grinding speed controlled at 300 to 700 rpm, liquid-to-bead ratio 1:(2-8).

9. A freeze-dried solid powder of albendazole nanocrystal, It is characterized in that The albendazole nanocrystal is prepared by freeze-drying the albendazole nanocrystal according to any one of claims 1 to 6.

10. A pharmaceutical preparation, It is characterized in that The albendazole nanocrystal freeze-dried solid powder is prepared by mixing the albendazole nanocrystal freeze-dried solid powder described in claim 9 with pharmaceutically acceptable excipients.

Citation Information

Patent Citations

  • Albendazole nanometer powder and preparation method thereof

    CN108403646A

  • Albendazole nanosuspension with relatively high bioavailability and preparation method of albendazole nanosuspension

    CN114224834A

  • Preparation method of albendazole nanocrystal

    CN116421601A

  • Nanocrystalline solid dispersion compositions and process of preparation thereof

    US20150132385A1

  • Prepartion of nanocrystals and nanaoparticles of narrow distribution and uses thereof

    US20180344645A1

Cited By

  • Veterinary albendazole tablet and preparation method thereof

    CN119632938A

  • Veterinary albendazole tablet and method for preparing the same

    CN119632938B